# Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

> **NCT00548847** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 15 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** GM-CSF
- **BIOLOGICAL:** Interferon-α-2b

## Key facts

- **NCT ID:** NCT00548847
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548847, "Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00548847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*